Asthma. chronic lower respiratory disease
Conditions
Interventions
Intervention 1: Intervention group:citrate magnesium,capsules 150 mg oral twice a day for two months. Intervention 2: Contol group:placebo,150 mg capsules oral lactose, twice a day for two months.
Treatment - Drugs
Intervention group:citrate magnesium,capsules 150 mg oral twice a day for two months
Contol group:placebo,150 mg capsules oral lactose, twice a day for two months
Sponsors
Abadan International Unit Of Ahwaz Jundishapur University
Eligibility
Sex/Gender
All
Age
19 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Men and women 19 to 55 years of age who met the Global Initiative for Asthma (GINA) guidelines in 2008, FEV1more than80%, variability FEV1less than 20-30% for mild asthma and FEV1=60-80%, variability FEV1more than 30% for moderate asthmatic; non smoker; who used only beta-agonist or inhaled corticosteroids. Exclusion criteria: evidence of cardiovascular disease, abnormal kidney function,other lung disease; alcohol abuse; uncontrolled hypertension; pregnancy or breastfeeding; have any change in own diet; current use of theophyline or leukotriene antagonists; any treatment likely to affect magnesium absorption or excretion, including diuretics or calcium containing medications; history of emergency room care or hospitalization for asthma in the last 6 months.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Force Vital Capacity. Timepoint: before intervention and two months after the intervention. Method of measurement: based on litter with spirometry.;Forced expiratory volume in one second. Timepoint: before intervention and two months after the intervention. Method of measurement: based on %liter with spirometry.;Density of interlukine 17 in blood. Timepoint: before intervention and two months after the intervention. Method of measurement: based on pico grams per milliliter with laboratory kit.;FEV1/FVC. Timepoint: before intervention and two months after the intervention. Method of measurement: with spirometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Magnesium concenteration in serum. Timepoint: before intervention and two months after intervention. Method of measurement: based on mg/dl with laboratory kit.;Level of magnesium intake. Timepoint: three times (two days and one weekend). Method of measurement: based on mg/d with 24 hours intake for three times.;Levels of quality of life. Timepoint: before intervention and two months after intervention. Method of measurement: numbers of quality of life quationnaire.;Level of asthma control. Timepoint: before intervention and two months after intervention. Method of measurement: numbers of asthma control quationnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNarges Fathi
Abadan International Unit of Ahwaz Jundishapur University
Outcome results
None listed